News

Entresto (sacubitril/valsartan) is intended for treating symptomatic chronic heart failure with left ventricular systolic dysfunction in patients who are aged from 1 to <18 years. Novartis global head

As part of the deal, both the entities will be involved in research activities to detect and improve LENSai in silico-generated antibodies. These antibodies are being developed as

The independent bid committee of Sensidose has recommended the cash offer. At present, the shares of Sensidose are listed on Spotlight Stock Market in Sweden. Sensidose is involved

As per the terms of the deal, OEP will receive exclusive rights from OncoVent to commercialise oregovomab in Taiwan. The licence will also cover related regulatory applications and

ENHERTU, which is a HER2 directed ADC, features a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload through a stable tetrapeptide-based cleavable linker. The approval of

A tumour infiltrating lymphocyte (TIL) therapy,  lifileucel is designed to treat patients with advanced (unresectable or metastatic) melanoma who advanced  on or after prior anti-PD-1/L1 therapy and targeted therapy.

Under the deal terms, Macomics will be responsible for identifying and characterising the antibody candidates against a new target leveraging its Enigmac macrophage drug discovery platform. Ono Pharmaceutical

Dewpoint’s discovery platform related to biomolecular condensates will be used to identify the drug candidates. The collaboration will enable combination of Novo Nordisk’s expertise in treating diabetes and

PBP1510 will mainly act on a tumour-specific protein called pancreatic adenocarcinoma upregulated factor (PAUF), which is overexpressed in most pancreatic cancer patients. PAUF overexpression is said to advance